e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension
Emilia M. Swietlik, Pavandeep Ghataorhe, Kasia I. Zalewska, John Wharton, Luke S. Howard, Dolores Taboada, John E. Cannon, Nicholas W. Morrell, Martin R. Wilkins, Mark Toshner, Joanna Pepke-Zaba, Christopher J. Rhodes
Source:
Eur Respir J, 57 (4) 2003201; 10.1183/13993003.03201-2020
Journal Issue:
April
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Emilia M. Swietlik, Pavandeep Ghataorhe, Kasia I. Zalewska, John Wharton, Luke S. Howard, Dolores Taboada, John E. Cannon, Nicholas W. Morrell, Martin R. Wilkins, Mark Toshner, Joanna Pepke-Zaba, Christopher J. Rhodes. Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension. Eur Respir J, 57 (4) 2003201; 10.1183/13993003.03201-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Eosinophils and airway nerves in asthma
Related content which might interest you:
Plasma metabolomics in chronic thromboembolic pulmonary hypertension
Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension
Year: 2020
Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension
Source: Eur Respir Rev 2015; 24: 272-282
Year: 2015
Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options
Source: Eur Respir Rev 2009; 18: 24-28
Year: 2009
Vasodilator treatment in chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2003 - Update on chronic thromboembolic pulmonary hypertension
Year: 2003
Evaluation of serum cytokines in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension with hypercholesterolemia
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020
Year: 2020
Sequential multimodal therapy in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension
Year: 2020
The ADAMTS13–VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension
Source: Eur Respir J, 53 (3) 1801805; 10.1183/13993003.01805-2018
Year: 2019
Genetic diagnostics in patients with chronic thromboembolic pulmonary hypertension
Source: International Congress 2019 – Novel methods, diagnostics and biomarkers in chronic lung diseases
Year: 2019
Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients
Source: Eur Respir J 2014; 44: 951-962
Year: 2014
Real-life data on the medical therapy of pulmonary arterial and chronic thromboembolic pulmonary hypertension
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
Platelet function in patients with chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2009 - Acute and chronic venous thromboembolic disease
Year: 2009
Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension?
Source: Eur Respir J 2014; 44: 842-845
Year: 2014
Chronic thromboembolic pulmonary hypertension: the evolving treatment landscape
Source: Eur Respir Rev 2015; 24: 173-177
Year: 2015
Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 272s
Year: 2005
Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Circulating microRNA signature and its novel involvement in pathogenesis of chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Year: 2012
Inflammatory cell accumulation in pulmonary arteries is associated with systemic inflammation in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease
Year: 2010
A roadmap for management of chronic thromboembolic pulmonary hypertension
Source: Eur Respir J, 54 (4) 1901295; 10.1183/13993003.01295-2019
Year: 2019
Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept